A study to investigate how budesonide and formoterol move through the body (pharmacokinetics) when delivered with different devices in participants aged 4 to less than 12 years old with asthma - COMPAIR

Exclusion Criteria

• - Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma.
• - History of life-threatening asthma defined as any asthma episode associated with loss of consciousness, intubation or admission to an intensive care unit.
• - History of severe asthma exacerbation within 8 weeks of Visit 1.
• - Inability to change from any budesonide therapy to another suitable corticosteroid.
• - Participants with a known hypersensitivity to budesonide and/or formoterol fumarate or any of the excipients of the product.
• - Not be able to refrain from consuming alcohol and smoking (including electronic cigarettes, vaping, and marijuana) from the time of screening until after the safety follow-up visit.
• - Unstable asthma.
• - Received regular maintenance treatment with prohibited anti-inflammatory or long-acting bronchodilator asthma medication.
• - Evidence of active liver disease.
• - Prolonged QT interval corrected for heart rate using Fridericia’s correction (QTcF).